New research suggests that GLP-1 receptor agonists, the blockbuster class of medicines that includes Ozempic and Wegovy, may lower the risk of serious bone fractures in people with type 2 diabetes. The findings, published in a large observational study, challenge long-held assumptions that rapid weight loss inevitably weakens bones.
Researchers analyzed health records from more than 133,000 adults aged 50 to 90 with type 2 diabetes in the United States between 2015 and 2022. They found that patients who started GLP-1 medicines had a 21% lower risk of fragility fractures over three years compared with those prescribed DPP-4 inhibitors, another common diabetes treatment.
Fragility fractures are breaks that occur from low-energy trauma, such as falling from standing height or less. People with type 2 diabetes face an elevated risk of such fractures despite often having normal or even higher bone density. The researchers attribute this to "lower bone strength, impaired bone microarchitecture, and accelerated bone loss."
The most pronounced reductions were seen in vertebral fractures, which dropped by 32%, and hip or femur fractures, which fell by 30%. Importantly, the protective effect was independent of changes in body weight and blood sugar levels, suggesting the drugs may act directly on bone tissue.
Implications for diabetes care
These findings offer reassurance for the millions of Europeans with type 2 diabetes who are prescribed GLP-1 medicines. In countries like Germany, France, and the UK, these drugs have become standard second-line treatments, and their use is expanding. The study's lead author noted that the results "challenge the assumption that weight loss from these drugs inevitably harms bone health."
However, the researchers caution that the study does not prove causation. Because it relied on observational data rather than a randomized clinical trial, other factors—such as physical activity, muscle strength, and baseline bone health—may have influenced the outcomes. The authors emphasize that patients should not change their medication without consulting their doctors.
Interestingly, the study found no protective effect among people taking GLP-1 medicines without type 2 diabetes. This suggests the benefits may be specific to the metabolic profile of diabetes, and that the findings may not apply to those using the drugs solely for weight management.
The results add to a growing body of evidence on the broader health effects of GLP-1 therapies. Earlier research has linked these drugs to cardiovascular benefits and kidney protection, but bone health has remained a concern. This study, while not definitive, provides a more nuanced picture.
For European health systems, where osteoporosis and fracture-related costs are substantial, any potential reduction in fracture risk could have significant implications. The study's authors call for further research, including randomized trials, to confirm the findings and explore the underlying mechanisms.
As the use of GLP-1 medicines continues to rise across the continent, this study offers a timely reminder that the benefits of these drugs may extend beyond weight loss and glucose control. Yet, as with all medical treatments, individual risks and benefits should be weighed carefully.
